Loading
CD40 sits on the cells that teach T cells what to attack. Agonist antibodies press it to turn cold tumours hot; the strongest signals so far are in pancreatic cancer with chemotherapy. This dossier gathers the 4 products (0 approved), 7 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
A TNF-receptor-superfamily member on antigen-presenting cells; the target of the CD40 agonist technology.
| Modality | Phase 2 | Phase 1 |
|---|---|---|
| Antibody 2 | - | |
| Small molecule 1 | - | |
| Vaccine or virus 1 | - |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 2 | Recruiting | IGNITE: A Phase 2 Study of Maintenance Combinatorial Myeloid Immunotherapy in Patients With Unresectable Pancreatic Ductal Adenocarcinoma | - | ||
| 1/2 | Recruiting | A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC) | - | ||
| 1/2 | Active | An Open-label Phase 1b/2 Study Assessing the Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | - | ||
| 1 | Completed | A Multicentre, Open Label, Non-randomised First in Human Study of NG-350A (Monotherapy), and NG-350A With a Check Point Inhibitor in Patients With Metastatic or Advanced Epithelial Tumours | - | ||
| 1 | Active | A Multicentre, Open-label, Non-randomized, Phase 1b Trial of NG-350A, a Tumour-selective Anti-CD40-expressing Adenoviral Vector, in Combination With Chemoradiotherapy in Locally Advanced Rectal Cancer (FORTRESS) | - | ||
| 1 | Completed | Immunotherapy Regimen Given After Targeted Local Cryolysis (TLC) for Patients With Advanced/Metastatic Castration-resistant Prostate Cancer (mCRPC) OR Those With Metastatic Prostate Cancer Who Refused Hormone Therapy and Chemotherapy. | - | ||
| 1 | Completed | A Multicentre, Open-label, Non-randomized, Phase 1a/1b Study of NG-350A, a Tumour-selective Anti-CD40-expressing Adenoviral Vector, in Combination With Pembrolizumab in Patients With Metastatic or Advanced Epithelial Tumours | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"CD40" OR ABSTRACT:"CD40" OR TITLE:"TNFRSF5" OR ABSTRACT:"TNFRSF5" OR TITLE:"CD40 molecule" OR ABSTRACT:"CD40 molecule" OR TITLE:"Bp50" OR ABSTRACT:"Bp50" OR TITLE:"p50" OR ABSTRACT:"p50") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD40, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/cd40.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/cd40.json. Licence CC BY-NC 4.0.